



## Coverage Guidelines: Gilenya (fingolimod)

---

### Policy

Network Health covers Gilenya (fingolimod) as a step care agent for *Network Health Together*<sup>®</sup>, *Network Health Forward*<sup>®</sup>, and *Network Health Extend* members who meet specific coverage criteria. Providers must get prior authorization, unless we have processed a claim for beta-interferon or glatiramer no more than 180 days before a claim for Gilenya. Gilenya is only available through our specialty pharmacy program as a pharmacy benefit.

### Covered conditions

Network Health covers Gilenya as a step care agent when a member meets all of the following criteria:

- The quantity prescribed does not exceed 30 capsules per 30 days, **and**
- We have processed a claim for beta-interferon (e.g., Avonex, Betaseron, Extavia, Rebif) or Copaxone (glatiramer) no more than 180 days before a claim for Gilenya; **or** we have processed a claim for Gilenya within the previous 180 days

Network Health requires prior authorization if the criteria described above are not met. Network Health covers Gilenya with prior authorization when a member meets the following criteria:

- Has a diagnosis of multiple sclerosis (relapsing forms), **and**
- The quantity prescribed does not exceed 30 capsules per 30 days, **and**
- Has tried and failed therapy with either beta-interferon (e.g., Avonex, Betaseron, Extavia, Rebif) or Copaxone (glatiramer); **or** the member's provider has documented clinical inappropriateness of treatment with either a beta-interferon or Copaxone; **or** is a new Network Health member already stabilized on Gilenya treatment

### Noncovered conditions

Network Health does not cover Gilenya for conditions not described in the covered conditions section.

### Definitions

**Multiple sclerosis (MS)** is a disease of the central nervous system marked by numbness, weakness, loss of muscle coordination, and problems with vision, speech, and bladder control. MS is an autoimmune disease in which the body's immune system attacks myelin, a key substance that serves as a nerve insulator and helps in the transmission of nerve signals.

**Relapsing** is a form of MS that patients tend to experience as an attack or series of attacks (exacerbations), followed by complete or partial remission.

---

These guidelines apply to *Network Health Together*, *Network Health Forward*, and *Network Health Extend* plans. Coverage is based on member benefits and eligibility; medical necessity review, where applicable; and the Network Health provider agreement. Adherence to these guidelines by a provider does not guarantee coverage. Network Health reserves the right to amend these guidelines at its discretion.



### Guidelines references

Cohen, J. A., Barkhof, F., Comi, G., Hartung, H., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., & Kappos, L. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *The New England Journal of Medicine*. 362, 402 – 415.

Gilenya [package insert]. (2010). *Novartis*.

Kappos, L., Radue, E., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., & Burtin, P. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *The New England Journal of Medicine*. 362, 387 – 401.